Industry Insights
-
Your 7 Decisions To Make Before MES Configuration
10/7/2026
Don't wait until manufacturing execution system (MES) configuration to answer these 7 questions. Define your manufacturing process before digitizing it.
-
Complete Response Letters For CGTs Share This Common Theme
10/7/2026
One expert’s analysis found CMC-related concerns in about 75% of complete response letters. He outlines a path to stronger CMC readiness for cell and gene therapies.
-
Finding The Therapeutic Window: Using Single-Cell Biology To Build More Selective T-Cell Engagers
10/6/2026
Cyril Konto, MD, discusses Shennon Biotechnologies programs in small cell lung cancer, ovarian cancer, and hepatocellular carcinoma, and spans antibody and TCR-based T-cell engagers.
-
DEA Reveals Hidden Costs Of Analytical Validation Guidelines
10/2/2026
By treating distinct validation guidelines as decision-making units, data envelopment analysis (DEA) allows for the mathematical evaluation of their resource efficiency.
-
What LSPA's Life Sciences Future Says About The Road Ahead For CGT
10/2/2026
The LSPA’s Life Sciences Future 2026 highlighted how shifting capital, M&A, global competition, and commercial pressures are reshaping CGT.
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
10/1/2026
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
CDMO Selection Beyond Capabilities And Price
9/30/2026
Some of the most useful information relevant to CDMO selection is also the hardest to obtain. Here are suggestions for uncovering data that tells the whole capability story.
-
August 2026 — CDMO Opportunities And Threats Report
9/28/2026
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
ICH M4Q(R2) And M16 Modernize The CTD For Digital Submissions
9/28/2026
A former FDA assessor explains how recent changes to the common technical document bring long-overdue updates to the submission process, accounting for greater data demands.
-
Inside Scaling Next-Gen MSCs Without Scaling Risk
9/25/2026
Here's why scaling MSC therapies requires maintaining product consistency, potency, and comparability as manufacturing evolves.